ADC Payload-Linker Manufacturing Market
完整報告名稱與涵蓋範圍
ADC Payload-Linker Manufacturing Market Size, Share & Trends Analysis Report, By Payload Class (Topoisomerase I Inhibitors, Auristatins and Maytansinoids, PBD and DNA-Damaging Payloads, Novel and Immunomodulatory Payloads), By Linker Type (Cleavable Linkers, Non-Cleavable Linkers), By Manufacturing Stage (Clinical-Scale Synthesis, Commercial-Scale Synthesis), By End User, By Region, and Segment Forecasts, 2026-2035
報告摘要
The ADC payload-linker manufacturing market covers the synthesis and supply of cytotoxic and immunomodulatory payloads, linkers and pre-assembled drug-linker intermediates used to build antibody-drug conjugates, at both clinical and commercial scale. Antibody production, conjugation and drug product manufacturing are addressed in separate studies and excluded here; proprietary linker-payload technology licensing revenue is included where it is commercialised as a supply arrangement.
Payload-linker chemistry has become a distinct specialty because high-potency compounds demand occupational exposure bands well below conventional APIs, multi-step syntheses with chiral centres and stringent impurity control. The success of topoisomerase I inhibitor ADCs has shifted demand from auristatin and maytansinoid payloads toward exatecan-derived and other camptothecin analogues, while cleavable linker designs, hydrophilic spacers and dual-payload concepts drive further chemistry complexity. Manufacturers are adding containment suites, continuous flow capabilities and analytical platforms, and originators are qualifying second sources to reduce single-supplier risk.
Europe and the United States lead in commercial-scale high-potency capacity, while China and India are expanding rapidly for clinical supply and cost-sensitive programs. Competition comprises high-potency chemistry specialists, integrated ADC CDMOs and reagent companies moving up the value chain.
The InsightAce study delivers revenue forecasts in US$ across all payload class, linker type, manufacturing stage and end user and regional segments for 2026-2035, alongside segment-level trend analysis, competitive landscape assessment and detailed company profiling.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global ADC Payload-Linker Manufacturing Market Snapshot
Chapter 4. Global ADC Payload-Linker Manufacturing Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Payload Class Estimates & Trend Analysis
5.1. Payload Class & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Payload Class:
5.2.1. Topoisomerase I Inhibitors
5.2.2. Auristatins and Maytansinoids
5.2.3. PBD and DNA-Damaging Payloads
5.2.4. Novel and Immunomodulatory Payloads
Chapter 6. Market Segmentation 2: By Linker Type Estimates & Trend Analysis
6.1. Linker Type & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Linker Type:
6.2.1. Cleavable Linkers
6.2.2. Non-Cleavable Linkers
Chapter 7. Market Segmentation 3: By Manufacturing Stage Estimates & Trend Analysis
7.1. Manufacturing Stage & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Manufacturing Stage:
7.2.1. Clinical-Scale Synthesis
7.2.2. Commercial-Scale Synthesis
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. End User & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
8.2.1. ADC Developers
8.2.2. ADC CDMOs and Bioconjugation Providers
Chapter 9. ADC Payload-Linker Manufacturing Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Lonza Group AG
11.2. WuXi XDC Cayman Inc.
11.3. Piramal Pharma Solutions
11.4. Sterling Pharma Solutions
11.5. Ajinomoto Bio-Pharma Services
11.6. Bachem Holding AG
11.7. Cerbios-Pharma SA
11.8. MedChemExpress LLC
11.9. Levena Biopharma
11.10. Creative Biolabs
11.11. Synaffix B.V. (Lonza)
11.12. Mersana Therapeutics, Inc.
11.13. NBE-Therapeutics (Boehringer Ingelheim)
11.14. Concortis Biosystems
11.15. Olon S.p.A.
圖表清單 List of Tables & Figures
Table 1. Global ADC Payload-Linker Manufacturing Market Revenue Forecast by Payload Class, 2026-2035 (US$ Mn)
Figure 1. Global ADC Payload-Linker Manufacturing Market Segmentation and Scope Overview
Table 2. Global ADC Payload-Linker Manufacturing Market Revenue Forecast by Linker Type, 2026-2035 (US$ Mn)
Figure 2. Global ADC Payload-Linker Manufacturing Market Share by Payload Class, 2026 & 2035
Table 3. Global ADC Payload-Linker Manufacturing Market Revenue Forecast by Manufacturing Stage, 2026-2035 (US$ Mn)
Figure 3. Payload Class Mix Shift Toward Topoisomerase I Inhibitor Chemistries, 2026-2035
Table 4. Global ADC Payload-Linker Manufacturing Market Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 4. High-Potency Containment and Synthesis Capacity by Provider and Region
Table 5. Global ADC Payload-Linker Manufacturing Market Revenue Forecast by Region, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific ADC Payload-Linker Manufacturing Growth Opportunity Analysis
Table 6. North America ADC Payload-Linker Manufacturing Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Competitive Positioning of Key ADC Payload-Linker Manufacturing Market Participants
Table 7. Europe ADC Payload-Linker Manufacturing Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Porter's Five Forces Analysis of the Global ADC Payload-Linker Manufacturing Market
Table 8. Asia Pacific ADC Payload-Linker Manufacturing Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Linker Design Trends Affecting Manufacturing Complexity and Cost
Table 9. Strategic Developments of Leading ADC Payload-Linker Manufacturing Market Participants, 2023-2026
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們